Oxford, UK: 2 August 2007: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announced that data from its Phase II clinical trial of TroVax in colorectal cancer patients who were also receiving chemotherapy under the FOLFOX regime has been published in the 1 August 2007 edition of Clinical Cancer Research, a journal of the American Association for Cancer Research (‘AACR’). AACR has issued the following announcement:
